A targeted extracorporeal therapy for endotoxemia: The time has come

Critical Care

Volumn 11, Issue 3, 2007, Pages

  Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ENDOTOXIN; ENDOTOXIN ANTIBODY; POLYMYXIN B; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; CHEMOLUMINESCENCE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DRUG EFFICACY; ENDOTOXEMIA; EVIDENCE BASED MEDICINE; EXTRACORPOREAL CIRCULATION; GRAM NEGATIVE INFECTION; HEMODYNAMICS; HEMOPERFUSION; HUMAN; LIMULUS LYSATE TEST; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL; BLOOD; INSTRUMENTATION; METHODOLOGY; NOTE; SEROLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ENDOTOXEMIA; ENDOTOXINS; HEMOPERFUSION; HUMANS; POLYMYXIN B; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 40749090391     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc5918     Document Type: Article

References (14)

1. Cruz DN Perazella MA Bellomo R de Cal M Polanco N Corradi V Lentini P Nalesso F Ueno T Ranieri VM Ronco C Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review Crit Care 2007 11 R47 10.1186/cc5780 17448226
2. Alexander C Rietschel ET Bacterial lipopolysaccharides and innate immunity J Endotoxin Res 2001 7 1571-1574 10.1179/096805101101532675 11581570
3. Opal SM The clinical relevance of endotoxin in human sepsis: A critical analysis J Endotoxin Res 2002 8 473-476 10.1179/096805102125001109 12697093
4. Klein DJ Derzko A Seely A Foster D Marshall J Marker or mediator? Changes in endotoxin activity as a predictor of adverse outcomes in critical illness Crit Care 2005 9 Suppl 1 161 10.1186/cc3224
5. Opal SM Scannon PJ Vincent JL White M Carroll SF Palardy JE Parejo NA Pribble JP Lemke JH Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock J Infect Dis 1999 180 1584-1589 10.1086/315093 10515819
6. Fink MP Delude RL Epithelial barrier dysfunction: A unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level Crit Care Clin 2005 21 177-196 10.1016/j.ccc.2005.01.005 15781156
7. Marshall JC Foster D Vincent JL Cook DJ Cohen J Dellinger RP Opal S Abraham E Brett SJ Smith T Mehta S Derzko A Romaschin A Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study J Infect Dis 2004 190 527-534 10.1086/422254 15243928
8. Singh S Evans TW Organ dysfunction during sepsis Intensive Care Med 2006 32 349-360 10.1007/s00134-005-0038-9 16474954
9. Romaschin AD Walker PM Endotoxin activity in whole blood by neutrophil chemiluminescenceVa novel analytical paradigm Clin Chem 2000 46 1504-1506 10973903
10. ALKharfy KM Kellum JA Matzke G Unintended immunomodulation: Part II. Effects of pharmacological agents on cytokine activity Shock 2000 13 346-360 10807009
11. Ziegler EJ Fisher CJ Jr Sprung CL Straube RC Sadoff JC Foulke GE Wortel CH Fink MP Dellinger RP Teng NN Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebocontrolled trial. The HA-1A Sepsis Study Group N Engl J Med 1991 324 429-436 1988827
12. McCloskey RV Straube RC Sanders C Smith SM Smith CR Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group Ann Intern Med 1994 121 1-5 8198341
13. Angus DC Birmingham MC Balk RA Scannon PJ Collins D Kruse JA Graham DR Dedhia HV Homann S MacIntyre N E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial. E5 Study Investigators JAMA 2000 283 1723-1730 10.1001/jama.283.13.1723 10755499
14. Shoji H Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin) Therapeutic Apheresis Dialysis 2003 7 108-114 10.1046/j.1526-0968.2003.00005.x 12921125